Publications by authors named "J D Chetwood"
Background/aims: There are spare data on comparative medication efficacy in fistulizing Crohn's disease (FCD), particularly with immunomodulator co-therapy. Persistence is a unique way to assess real-world outcomes.
Methods: The persistence of all dispensed biological agents were analysed from the Australian Pharmaceutical Benefits Scheme (PBS) registry data 2005-2021 for FCD.
Letter: Bowel Preparation Quality in Patients With Crohn's Disease.
Aliment Pharmacol Ther
January 2025
Article Synopsis
- New advanced therapies for inflammatory bowel diseases (IBDs) require enhanced risk management strategies to ensure patient safety during treatment.
- A comprehensive set of eight statements was developed through literature review and expert consensus, focusing on assessments and vaccinations needed before starting therapies like JAK inhibitors and S1P modulators.
- Key findings include the necessity for infectious disease screenings, updated vaccination protocols, and specific risk assessments for malignancies and cardiovascular issues to reduce IBD complications associated with these advanced treatments.